P-glycoprotein-mediated intestinal and biliary digoxin transport in humans

scientific article published in March 2003

P-glycoprotein-mediated intestinal and biliary digoxin transport in humans is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1067/MCP.2003.27
P698PubMed publication ID12621387

P2093author name stringMichel Eichelbaum
Martin F Fromm
Hartmut Glaeser
Thomas Mürdter
Monika Hitzl
Siegfried Drescher
P433issue3
P407language of work or nameEnglishQ1860
P921main subjectdigoxinQ422222
P304page(s)223-231
P577publication date2003-03-01
P1433published inClinical Pharmacology & TherapeuticsQ1101529
P1476titleP-glycoprotein-mediated intestinal and biliary digoxin transport in humans
P478volume73

Reverse relations

cites work (P2860)
Q44231662A novel screening strategy to identify ABCB1 substrates and inhibitors
Q50924621A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers.
Q24799859Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring
Q64107533Changes in the Expression of Aquaporin-3 in the Gastrointestinal Tract Affect Drug Absorption
Q37993655Circadian clock genes and implications for intestinal nutrient uptake
Q91069615Clinical Aspects of Transporter-Mediated Drug-Drug Interactions
Q35620664Clinical relevance of P-glycoprotein in drug therapy
Q35776626Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion
Q49369243Different modulation of Panax notoginseng on the absorption profiling of triptolide and tripterine from Tripterygium wilfordii in rat intestine
Q33942474Diurnal rhythmicity in the transcription of jejunal drug transporters
Q36419290Drug transporters in pharmacokinetics
Q89336517Effect of carbamazepine on the pharmacokinetics of paliperidone extended-release tablets at steady-state
Q46807639Effect of lasofoxifene on the pharmacokinetics of digoxin in healthy postmenopausal women
Q46743429Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study
Q45188831Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination
Q37705351Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation
Q51735063Further Study of Influence of Panax notoginseng on Intestinal Absorption Characteristics of Triptolide and Tripterine in Rats with Tripterygium wilfordii.
Q40895593Gastrointestinal absorption and metabolism of hesperetin-7-O-rutinoside and hesperetin-7-O-glucoside in healthy humans
Q28176037Herb-drug interactions: a literature review
Q37811970In Vivo Probes of Drug Transport: Commonly Used Probe Drugs to Assess Function of Intestinal P-glycoprotein (ABCB1) in Humans
Q60787030Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux
Q42129498Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes
Q40184411Intestinal drug transporter expression and the impact of grapefruit juice in humans
Q36985043Intestinal permeability and its relevance for absorption and elimination
Q36960535Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety
Q57726142Metabolic and Efflux Properties of Caco-2 Cells Stably Transfected with Nuclear Receptors
Q36495774Methods to evaluate biliary excretion of drugs in humans: an updated review
Q37515418Organic cation transporters and their roles in antiretroviral drug disposition
Q34349313Overcoming drug resistance by regulating nuclear receptors
Q46922851Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin
Q37957801Pharmacokinetic considerations in Roux-en-Y gastric bypass patients
Q33204911Pharmacokinetic interactions of drugs with St John's wort
Q56832659Plasma LDL cholesterol has no impact on P-glycoprotein (MDR1/ABCB1) activity in human peripheral blood mononuclear cells
Q37139856Prediction of human pharmacokinetics-biliary and intestinal clearance and enterohepatic circulation
Q33267032Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis.
Q44653786Rifampicin reduces plasma concentrations of celiprolol
Q39542449Rifampin and digoxin induction of MDR1 expression and function in human intestinal (T84) epithelial cells.
Q48301397Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design.
Q46578287Role of enterohepatic recirculation in drug disposition: cooperation and complications
Q46890019Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies
Q28269209Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities
Q34657381Sucralose, a synthetic organochlorine sweetener: overview of biological issues
Q38156114Suitability of digoxin as a P-glycoprotein probe: implications of other transporters on sensitivity and specificity
Q35956193The ABC transporters MDR1 and MRP2: multiple functions in disposition of xenobiotics and drug resistance
Q37669983The Effects of Pregnenolone 16α-Carbonitrile Dosing on Digoxin Pharmacokinetics and Intestinal Absorption in the Rat.
Q80201270The association of ABCB1 polymorphisms and elevated serum digitoxin concentrations in geriatric patients
Q39655447The impact of thyroid disease on the regulation, expression, and function of ABCB1 (MDR1/P glycoprotein) and consequences for the disposition of digoxin
Q37905033Transporter-mediated drug-drug interactions

Search more.